As Biotechnology businesses, Editas Medicine Inc. (NASDAQ:EDIT) and Coherus BioSciences Inc. (NASDAQ:CHRS), are affected by compare. This especially applies to their institutional ownership, profitability, risk, analyst recommendations, dividends, earnings and valuation.
Earnings and Valuation
|Gross Revenue||Price/Sales Ratio||Net Income||Earnings Per Share||Price/Earnings Ratio|
|Editas Medicine Inc.||29.48M||32.59||121.09M||-2.67||0.00|
|Coherus BioSciences Inc.||N/A||0.00||195.81M||-3.13||0.00|
Table 1 demonstrates Editas Medicine Inc. and Coherus BioSciences Inc.’s gross revenue, earnings per share and valuation.
Table 2 shows Editas Medicine Inc. and Coherus BioSciences Inc.’s net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
|Editas Medicine Inc.||-410.75%||-53.1%||-31.1%|
|Coherus BioSciences Inc.||0.00%||-741.7%||-126.2%|
Editas Medicine Inc.’s Current Ratio and Quick Ratio are 13.1 and 13.1 respectively. The Current Ratio and Quick Ratio of its competitor Coherus BioSciences Inc. are 5.3 and 5.3 respectively. Editas Medicine Inc. therefore has a better chance of paying off short and long-term obligations compared to Coherus BioSciences Inc.
The next table highlights the delivered recommendations and ratings for Editas Medicine Inc. and Coherus BioSciences Inc.
|Sell Ratings||Hold Ratings||Buy Ratings||Rating Score|
|Editas Medicine Inc.||0||0||0||0.00|
|Coherus BioSciences Inc.||0||0||1||3.00|
On the other hand, Coherus BioSciences Inc.’s potential upside is 98.44% and its average price target is $28.
Institutional and Insider Ownership
Institutional investors owned 75.7% of Editas Medicine Inc. shares and 95.7% of Coherus BioSciences Inc. shares. 2.6% are Editas Medicine Inc.’s share owned by insiders. On the other hand, insiders owned about 0.1% of Coherus BioSciences Inc.’s shares.
Here are the Weekly, Monthly, Quarterly, Half Yearly, Yearly and YTD Performance of both pretenders.
|Performance (W)||Performance (M)||Performance (Q)||Performance (HY)||Performance (Y)||Performance (YTD)|
|Editas Medicine Inc.||-6.96%||1.29%||-6.69%||-19.81%||12.45%||-5.66%|
|Coherus BioSciences Inc.||-10.04%||-20.27%||-44.41%||-37.81%||17.75%||13.07%|
For the past year Editas Medicine Inc. has -5.66% weaker performance while Coherus BioSciences Inc. has 13.07% stronger performance.
Editas Medicine Inc. beats on 7 of the 10 factors Coherus BioSciences Inc.
Editas Medicine, Inc. operates as a genome editing company. It focuses on treating patients with genetically defined diseases by correcting their disease causing genes. It is developing a proprietary genome editing platform based on CRISPR technology to target genetically defined diseases with an initial focus on debilitating illnesses where there are no approved treatments. Editas Medicine, Inc. has a collaboration and license agreement with Juno Therapeutics, Inc. for the research and development of engineered T cells with chimeric antigen receptors and T cell receptors; and collaboration, option, and license agreement with Adverum Biotechnologies, Inc. to explore the delivery of genome editing medicines for the treatment of inherited retinal diseases. The company was formerly known as Gengine, Inc. and changed its name to Editas Medicine Inc. in November 2013. Editas Medicine, Inc. was founded in 2013 and is based in Cambridge, Massachusetts.
Coherus BioSciences, Inc., a late-stage clinical biologics platform company, focuses on developing and commercializing biosimilar products worldwide. The companyÂ’s product candidates include CHS-1701, a pegfilgrastim biosimilar candidate, which is used for the treatment of febrile neutropenia; CHS-0214, an etanercept biosimilar candidate, which is in various phases of clinical trials for the treatment of ankylosing spondylitis, juvenile idiopathic arthritis, psoriatic arthritis, rheumatoid arthritis, and psoriasis; and CHS-5217, a bevacizumab biosimilar candidate, which is in preclinical stage for the treatment of metastatic colorectal cancer, nonÂ–small cell lung cancer, metastatic kidney cancer, advanced cervical cancer, platinum-resistant ovarian cancer, and recurrent glioblastoma. Its product candidates also comprise CHS-1420, an adalimumab biosimilar candidate, which is in various phases of clinical trials to treat ankylosing spondylitis, BehÃ§et’s Disease, CrohnÂ’s Disease, juvenile idiopathic arthritis, psoriasis, psoriatic arthritis, rheumatoid arthritis, and ulcerative colitis; and CHS-3351, a ranibizumab biosimilar candidate, which is in preclinical stage for the treatment of neovascular (wet) age-related macular, degeneration, macular edema following retinal vein occlusion, diabetic macular edema, and diabetic retinopathy. Coherus Biosciences, Inc. has license agreement with Daiichi Sankyo Company, Limited; Baxalta Incorporated, Baxalta US Inc., and Baxalta GmbH; Genentech, Inc.; and Selexis SA. The company was formerly known as BioGenerics, Inc. and changed its name to Coherus Biosciences, Inc. in April 2012. Coherus Biosciences, Inc. was founded in 2010 and is headquartered in Redwood City, California.